Clinical Trial Update: Study of the Effects of Fabrazyme Treatment on Lactation and Infants [Phase 4]

View source ↗

Summary

Phase 4 trial update on Fabrazyme (agalsidase beta) evaluating effects on lactation and infants in Fabry disease, with terminated status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Fabry Disease, Alpha Galactosidase A Deficiency | Phase 4 | Status: TERMINATED | Results posted: 2024-04-10